An experimental MYC inhibitor shrank tumors in mice by up to 100 percent when paired with immunotherapy, doubling the effect seen with the drug alone, researchers reported at the 38th EORTC-NCI-AACR Symposium in Barcelona on Friday.
The peptide drug OMO-103, developed by Peptomyc and tested in the Phase I MYCure trial, targets the MYC protein that drives uncontrolled growth in roughly 70 percent of human cancers. Until now, MYC has been considered “undruggable” because it lacks a stable binding pocket for conventional small molecules. OMO-103 mimics a dominant-negative helix that disrupts MYC’s interaction with its partner Max, blocking transcription of growth genes.
“When we experimentally removed T cells, OMO-103 still inhibited tumor growth, confirming its direct effect on cancer cells, but its efficacy was reduced by roughly half,” said Laura Soucek, ICREA research professor at the Vall d’Hebron Institute of Oncology (VHIO) and co-founder of Peptomyc. “This tells us that the immune response makes an important contribution to the full therapeutic effect of MYC inhibition.”
The findings matter because resistance to current targeted therapies and checkpoint inhibitors remains the primary cause of death in non-small cell lung cancer (NSCLC), which accounts for 85 percent of lung cancers. KRAS mutations, present in 25–30 percent of NSCLC, hyperactivate MYC, making this pathway a logical convergence point for combination strategies.

In Plain English: The Clinical Takeaway
- OMO-103 attacks cancer two ways: it stops tumor cells from dividing and strips away their camouflage so T cells can recognize and kill them.
- Early human data suggest patients whose tumors show interferon and TNF-superfamily activation are more likely to benefit, offering a potential biomarker for future trials.
- Combining OMO-103 with agonists of OX40 or 4-1BB — proteins that turbocharge T cells — produced dramatic responses in mice, but these are preclinical results, not clinical expectations.
Dual Mechanism Uncovered in Patient-Derived Models
Soucek’s team first treated tumor samples from KRAS-mutant NSCLC patients with OMO-103 in the lab. CD4⁺ and CD8⁺ T cells infiltrated the tissue and showed activation markers, indicating the drug remodels the tumor microenvironment from “cold” to “hot.” Depleting T cells in vivo cut the drug’s efficacy by 50 percent, confirming the immune system contributes half the therapeutic effect.
Correlative analysis of biopsies and blood from MYCure trial participants — spanning pancreatic, colorectal, and NSCLC cohorts — revealed that clinical benefit correlated with upregulation of interferon signaling and TNF-superfamily pathways. Patients with progressive disease lacked these signatures. “Because we are looking at a small number of clinical samples, these observations should be considered exploratory,” Soucek cautioned.
Combination Data Drive Next Trial Designs
In immunocompetent mouse models of lung cancer, OMO-103 monotherapy yielded objective response rates (ORR) of 29–37 percent depending on the experiment. Adding an OX40 agonist raised ORR to 89 percent. A 4-1BB agonist pushed ORR to 100 percent, with complete regressions in two of seven animals. EurekAlert noted these combinations provide “strong proof of concept for testing these combinations further.”
Ryan Corcoran, AACR co-chair of the ENA Symposium at Harvard Medical School, who was not involved in the research, said: “These data suggest that a MYC inhibitor may work against cancer cells in two important ways. First, the inhibitor may work directly on cancer cells to slow their growth, but second, the inhibitor may also help the immune system find and destroy tumor cells. These results provide an important basis for future patient trials combining a MYC inhibitor with other treatments designed to help the body’s immune response to cancer cells.”
From Undruggable to First-in-Class: Regulatory Path Forward
The MYCure Phase I trial (NCT04808362) established safety and pharmacokinetics across solid tumors; a recommended Phase II dose has been defined. Peptomyc, a VHIO spin-out, holds the intellectual property. The European Organisation for Research and Treatment of Cancer (EORTC) sponsored the symposium presentation.
OMO-103 is an experimental MYC inhibitor being tested in clinical trials.
Contraindications & When to Consult a Doctor
OMO-103 remains investigational and is not approved for any indication.
Peptomyc is a spin-off from the Vall d’Hebron Institute of Oncology (VHIO) founded by Dr. Laura Soucek, Dr. Marie-Eve Beaulieu, VHIO and ICREA. The company employs 15 people and develops cell-penetrating mini-proteins derived from Omomyc to directly inhibit MYC, a target long considered undruggable.
Its lead candidate, OMO-103, completed a Phase I study in solid tumor patients with results published in Nature Medicine in February 2024. Peptomyc has since initiated a Phase Ib trial in pancreatic ductal adenocarcinoma combining OMO-103 with standard of care.
“We will still need to carry out more experiments including prospective clinical testing,” Soucek said. “The ultimate goal is to evaluate rational combinations of MYC inhibition with immunotherapies in the clinic.”
References
- Soucek L, et al. MYC inhibition remodels the tumor microenvironment and synergizes with immunotherapy. Presented at: 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; Nov 20, 2026; Barcelona, Spain.
- MYCure Phase I Trial (NCT04808362). ClinicalTrials.gov.
- European Organisation for Research and Treatment of Cancer (EORTC). Nov 20, 2026.
- Corcoran RB. ENA Symposium, AACR. Nov 20, 2026.
- Constanze Lohse: These Three Nutrients Recommended for Over-60s
- Disabling Cellular Recycling Gene Boosts Membrane Protein Yields for Drug Discovery
- Pope Leo XIV Cleared for South America Tour After Lung Cancer Surgery (newsdirectory3.com)
- Jax Taylor Reveals Kidney Cancer Surgery; Kelce, Bure Podcast Comments (archynewsy.com)